Home| About us| Widget| login/register| For authors| For reviewers |Submit a paper
(close)

(Ctrl-click to select multiple journals)


How should we address you?

Your email address


 Yes, sign up now
 Sign up for general news too

Privacy Statement
 
 
 

Retrovirology: Research and Treatment

Synopsis: An open access, peer reviewed electronic journal that covers human and animal retrovirus research and treatment.


Indexing: 4 major databases. Pubmed indexing for NIH-funded research.

Processing time: Decision in 2 weeks for 90% of papers.

Visibility: Most popular article read 200+ times.

View factor
for journal
17422


About this journal

ISSN: 1178-1238


Aims and scope:

Retrovirology: Research and Treatment is an international, open access, peer reviewed journal which considers manuscripts on all areas of human and animal retrovirus research and treatment. The journal is particularly interested in human immunodeficiency virus (HIV) and human T-cell leukaemia virus (HTLV).

Editorial standards and procedures:

Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers.  Reviewers are required to provide fair, balanced and constructive reports.  

Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair.  Appeals are considered by the Editor in Chief or Associate Editor.

Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.

Indexed by:

  • CAS
  • DOAJ
  • Google Scholar
  • OAIster

National Institutes of Health Public Access Policy compliant:

As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.

If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf. 



 
 
 


HIV-1 Integrase Strand Transfer Inhibitors: Novel Insights into their Mechanism of Action

Authors: Krishan K. Pandey and Duane P. Grandgenett
Publication Date: 05 Nov 2008
Retrovirology: Research and Treatment 2008:2 11-16

Krishan K. Pandey and Duane P. Grandgenett

Institute for Molecular Virology, Saint Louis University Health Sciences Center, Saint Louis, MO 63104. U.S.A.

Abstract

Human immunodeficiency virus type-1 integrase (IN) is a new and novel target for inhibitors. Strand transfer inhibitors effectively prevent concerted integration of viral DNA by IN into the host chromosomes. Raltegravir is the first approved strand transfer inhibitor for the treatment of HIV-1/AIDS. We propose a mechanistic hypothesis as to “when and where” these inhibitors are active in virus-infected cells. Using native agarose gel electrophoresis, we identified a transient synaptic complex (SC) wherein IN non-covalently juxtaposes two viral DNA ends. SC possesses many properties associated with the cytoplasmic preintegration complex (PIC) in infected cells, including concerted integration. Our results show that the strand transfer inhibitors effectively “trap” or inactivate the SC preventing concerted integration. It follows that the IN-viral DNA complex is “trapped” by the inhibitors via a transient intermediate within the cytosolic PIC before entry into the nucleus.

Categories: Retrovirology


Post comment




No comments yet...Be the first to comment.

Bookmark this article

LINKEDIN FACEBOOK

Add to Mixx! MIXX YAHOO! BUZZ

PERMALINK DIGG


Sign up for free journal updates

How should we address you?
Your email address
 Yes, sign up now




Related journals...